SAN FRANCISCO, Dec. 6, 2012 /PRNewswire-USNewswire/ -- The nonprofit Scleroderma Research Foundation (SRF) welcomes Andrew Tager, MD to present "New Directions for Scleroderma Treatments: Understanding the Basis for Current Clinical Trials" on December 14, 2012 at 11 a.m. PST. This free webinar will describe current scleroderma clinical trials and new treatments on the horizon.
Dr. Tager is Assistant Professor of Medicine at Harvard Medical School, with appointments in the Center for Immunology and Inflammatory Diseases and the Pulmonary and Critical Care Unit of the Massachusetts General Hospital (MGH). He is also Co-Director of the MGH Interstitial Lung Disease Clinic, focusing on patients with lung fibrosis, including those with scleroderma.
Dr. Tager is a clinician/scientist whose work aims to find new ways to inhibit and prevent the progression of fibrotic diseases and promote healing of scarred organs. With clinical trials currently planned that target a chemical promoting fibrosis in scleroderma skin and idiopathic pulmonary fibrosis, Dr. Tager is uniquely qualified to share how research is translating into potentially new therapeutics.
Friday, December 14, 2012 from 11:00 a.m. – 12:00 p.m. PST, including a question and answer session. The Webinar will be available for later viewing on the SRF website.
Register online at www.sclerodermaRESEARCH.org.
About Scleroderma Research Foundation:
The Scleroderma Research Foundation is America's leading nonprofit investor in scleroderma research. It was founded in San Francisco in 1987 by scleroderma patient Sharon Monsky who lost her battle to the disease in 2002. Monsky's legacy lives on through the organization, chaired by Luke Evnin, Ph.D., managing partner of MPM Capital, one of the world's largest dedicated investors in life sciences.
The Foundation's collaborative approach is enabling scientists from leading institutions, academia and industry to work together and develop an understanding of how scleroderma begins, how it progresses and what can be done to slow, halt or reverse the disease process.
SOURCE Scleroderma Research Foundation